Revolutionizing Autoimmune Disease Treatment: A Breakthrough Approach

TLDRNon-munosuppressive treatments for autoimmune diseases offer hope for the 200 million affected individuals. This video explores the innovative oral treatment being developed by Promo Therapeutics, starting with Crohn's disease as a focus. By targeting disruptions in the microbiome and genetic mutations, the drug candidate has shown promising results in reversing symptoms in mouse models. Clinical trials are expected within the next two years.

Key insights

🔬Non-munosuppressive treatments for autoimmune diseases are in high demand, as existing treatments often come with serious side effects.

💡Promo Therapeutics is developing an oral treatment for autoimmune diseases, starting with Crohn's disease.

🐭The drug candidate has successfully reversed symptoms in mouse models for Crohn's disease, outperforming standard care.

⏳Clinical trials for the drug candidate are expected within the next two years.

🌟The innovative approach by Promo Therapeutics offers hope for improved treatment options and quality of life for autoimmune disease patients.

Q&A

What are autoimmune diseases?

—Autoimmune diseases are conditions in which the immune system mistakenly attacks the body's own cells and tissues.

Why are non-munosuppressive treatments important?

—Non-munosuppressive treatments are important as they offer effective treatment options without compromising the overall immune system.

What is Crohn's disease?

—Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract.

How does Promo Therapeutics' treatment work?

—Promo Therapeutics' treatment targets disruptions in the microbiome and genetic mutations associated with autoimmune diseases, aiming to restore a natural process that is disrupted in patients.

When will clinical trials be conducted?

—Clinical trials for Promo Therapeutics' drug candidate are expected to take place within the next two years.

Timestamped Summary

00:00Katarina, the founder and CEO of Promo Therapeutics, introduces their mission to develop non-munosuppressive treatments for autoimmune diseases.

00:26Crohn's disease is highlighted as their starting point due to its impact on the gastrointestinal tract.

00:41The treatment targets disruptions in the microbiome and genetic mutations that contribute to autoimmune diseases.

00:51The drug candidate has shown promising results in reversing symptoms in mouse models for Crohn's disease.

00:59Clinical trials are expected to be conducted within the next two years.

Browse more